Abstract
Background Deep brain stimulation (DBS) of the subthalamic nucleus (STN) in Parkinson’s disease (PD) that is more precisely focused to the desired target structure may avoid nearby structures that are responsible for undesired side effects.
Objective Comparing the long-term effects of STN-DBS with segmented or ring contacts on motor and non-motor symptoms in akinetic-rigid PD patients.
Methods This study was a prospective randomized clinical trial. At 6-months postoperatively, the optimal omnidirectional (OS) and directional (DS) stimulation contacts were compared in MedOFF within a double-blind cross-over design, both acutely (within one day) and chronically, i.e., after 3-week stimulation blocks of each condition. The examination included motor and non-motor evaluations (e.g., cognition, mood and quality of life). Importantly, the stimulation intensity of the optimal DS was adjusted such that the total electrical energy delivered (TEED) was equivalent to the TEED of the optimal OS.
Results There were no significant differences between OS and DS with regard to all outcome parameters, with 30% less stimulation intensity of the latter. Notably, OS scored (non-significantly) better than DS in all motor and non-motor measures apart from the cognitive evaluation, where OS led to a deterioration of executive functions. However, in 3 of 19 patients, the stimulation intensity of DS needed to be increased above the TEED-estimated values to reach the motor benefits of OS.
Conclusions Reliable comparisons between OS and DS require long-term clinical evaluations. A potential differential influence on motor and non-motor symptoms needs to be investigated in future confirmatory studies.
Registration: ClinicalTrials.gov: NCT03548506
Competing Interest Statement
A.G. was supported by research grants from Medtronic, Abbott, Boston Scientific, all of which were unrelated to this work. D. W. was supported by travel grants, speaker honoraria and research grants from Abbott, Abbvie, Bial, Boston Scientific, Medtronic, Kyowa Kirin, Stadapharm, all of which were unrelated to this work.
Clinical Trial
NCT03548506
Funding Statement
This investigator-initiated trial was supported by Abbott / St. Jude Medical (SANTOP). The funding had no impact on the study design, on the collection, analysis and interpretation of data, on the writing of the report or on the decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Medical Faculty of the University of Tuebingen gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding author
